DRUG
Double trigger
Triptorelin (0.2 mg/S.C ) and HCG (10000 IU/I.M) are administered 38 to 39 h and 35 to 36 h prior to ovum pick-up., respectively.
Triggering Oocyte Maturation in POSEIDON Group 3 and 4 Poor Responders Using Double Trigger or HCG Trigger
Status
Not yet recruiting
Phase
Phase 2
Enrollment
164
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The aim of this randomized controlled study is to compare the efficacy of double trigger protocol \[ the co-administration of GnRH agonist with HCG ( 38 - 39 and 35 - 36 h prior to ovum pick-up, respectively \] with HCG in triggering ovulation in patients with expected poor response to ovarian stimulation
Interventions
Treatment arms and agents.
DRUG
HCG trigger
HCG (10000 IU/I.M) is administered 35 to 36 h prior to ovum pick-up.
Timeline
From registration to results.
First posted
May 6, 2026
Study start
Jun 1, 2026
Primary completion
Dec 1, 2027
Study completion
Apr 1, 2028
Results posted
Not reported
Registry updated
May 6, 2026
Outcomes
What the study measures.
Primary outcomes
Metaphase-II oocytes rate
Time frame · Ten to fifteen days after starting ovarian stimulation
Number of MII oocyte/ number of cumulus oocyte complex
Secondary outcomes
Clinical pregnancy rate
Time frame · Five weeks after embryo transfer
Presence of intrauterine gestational sac detected by transvaginal ultrasound
Ongoing pregnancy Rate
Time frame · Eighteen weeks after embryo transfer
Pregnancies continued beyond 20 weeks gestation
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 40 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: * POSEIDON group 3 and 4 * GnRH antagonist IVF cycle Exclusion Criteria: * Hypogonadotrophic hypogonadism * Endometriosis * History of recurrent abortion
Study locations
1 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Bedaya Hospital
Giza, Giza Governorate, Egypt
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Triptorelin.
NCT IDStudyPhase / statusEnrollmentUpdated
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
ECOG-ACRIN Cancer Research Group · Prostate Carcinoma
Phase 3
Active, not recruiting
27
2026-07
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
RenJi Hospital · Prostate Cancer · Prostate
Phase 2
Not yet recruiting
200
2026-07
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
Debiopharm International SA · Central Precocious Puberty
Phase 3
Active, not recruiting
56
2026-07
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic · Recurrent Castration-Sensitive Prostate Carcinoma · Recurrent Prostate Cancer
Phase 2
Recruiting
532
2026-07
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Children's Oncology Group · Hematopoietic and Lymphatic System Neoplasm · Malignant Solid Neoplasm
Phase 3
Recruiting
60
2026-07
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
Ipsen · Early-stage Breast Cancer
Not applicable
Completed
450
2026-07
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD · Prostate Cancer · BRCA1 Mutation
Phase 2
Active, not recruiting
32
2026-07
Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis
Li-jun Ding · Deep Infiltrating Endometriosis (DIE) · Infertility
Phase 4
Recruiting
120
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.